Currently, targeted protein degradation (TPD) drug discovery has been gaining increased attention in the industry. As an emerging TPD technology, antibody-based PROTACs are developed that overcome the limitations of classical PROTACs that can only target intracellular proteins. BOC Sciences, as a leading contract service provider in drug discovery and research, has the capability and commitment...